ARM today released its 2019 Annual Report and Sector Year in Review, highlighting the organization’s key priorities and initiatives, as well as offering an in-depth look at trends and metrics for the cell therapy, gene therapy, and tissue engineering sector. ARM, which celebrated its 10th anniversary in 2019, is the premier international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector.

Key findings include:

• Globally, companies developing gene and cell therapies and other regenerative medicines raised nearly $10 billion in 2019, the second highest year on record. Venture financings were particularly strong, making up more than $4 billion in global financings – a 33% increase over 2018.
• There were 1,066 clinical trials underway worldwide by year-end 2019. The report includes figures on clinical trials by phase, technology type, and indication. 10+ product candidates are poised for approval, and the number of approved gene therapies will likely double in the next one to two years.
• Companies headquartered in Europe raised $3 billion, the strongest year on record, and were sponsoring 260 clinical trials by the end of the year.
• There is a supportive policy environment for regenerative medicines, with policymakers showing a strong interest in promoting the development of, and patient access to, these innovative therapies.